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Introduction
Prostate cancer is the most common non-skin cancer among men in the United States. This disease appears to run in families; many men who have close relatives with prostate cancer are at an increased risk of developing this disease themselves. Furthermore, such men might respond differently to treatment than men without a family history of prostate cancer. One possible explanation for the familiality of prostate cancer is genetics, and recent research has suggested some regions in DNA that might harbor alterations that increase the risk. We are studying brothers with prostate cancer in order to investigate the potential relation between genetic factors and their disease. The brothers are being recruited into the study from registries at Case Western Reserve University, the Cleveland Clinic Foundation (both in Cleveland), and the Henry Ford Health System (in Detroit). More specifically, we are contacting men who have been diagnosed with prostate cancer at these institutions to see if they have brothers and whether they would be willing to join our study. Since we are focusing on genetic factors, we are only contact those men in the registries who were aged 70 or younger when they were diagnosed. Our goal was to recruit the equivalent of 200 pairs of brothers into the study. We are collecting blood from the men, as well as questionnaire information. From the blood we will get DNA, and then use this information look at those genes that plausibly could lead to prostate cancer, based on current scientific evidence. In particular, we are studying whether the brothers with prostate cancer inherit certain forms of the genes more often than expected by chance, and whether such forms of these genes are associated with the aggressiveness of prostate cancer. If so, this implicates such genes in the development and/or aggressiveness of prostate cancer. The information from this study will help provide men with additional knowledge about their risk of prostate cancer and, if they are already diseased, how genes might influence their response to treatment.
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Body
Below we describe out research accomplishments with respect to the original Statement of Work. For focus and clarity we reproduce the approved tasks that were proposed for completion by the end of year 1. We then note our corresponding accomplishments, pointing out any issues arising during the course of this work. Task 2 was also initiated under the small pilot grant. Here we have been successful in building a database that contains contact information from our registries for 3000 potential probands, twice the number initially proposed. To date, we have sent an initial letter describing the study to over onethird of these men, and then contacted them to determine their eligibility / willingness to take part in the study. (Below we give more details on subject recruitment.) Once a proband was deemed to be eligible for taking part in the study, and indicated a willingness to join in our research project (per Task 2), we sent introductory letters to their brothers. This has been successfully followed with recruitment phone calls to enroll them into the study with their consent. We have successfully collected and stored blood and questionnaire information from 519 subjects, arising from 291 sibling sets. For these sets, some contain more than one brother. Ninety-nine of these sets only include a single sibling at the present time (we are currently bringing the corresponding siblings into the study). Over 50% of the sibling sets constitute brothers discordant for prostate cancer. Since discordant brothers will likely be less statistically powerful than concordant brothers, we are continuing our recruitment into year 2, and will ultimately have well beyond the initially proposed 200 pairs. In addition, we are now collaborating with another sib-pair study (PI William Catalona) to increase the total number of concordant sib-pairs available for analysis. Sib-pairs collected here are presently being genotyped for a genome-wide scan in conjunction with sib-pairs Dr. Catalona has collected over the past decade. This effort should result in more power than otherwise available to us, and hence potentially more promising scientific results.
While recruitment was ongoing during year 1, we have also evaluated the relation between a recently reported polymorphism in the CYP3A4 gene and prostate cancer aggressiveness among Africa-Americans. Our results indicate that the polymorphism is positively associated with aggressiveness at presentation, as measured by tumor stage and grade. This work has been accepted for publication in Cancer Epidemiology, Biomarkers, and Prevention, and is included here as Appendix 2.
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Key Research Accomplishments
During the initial year of this grant we have produced the following key research accomplishments.
• Developed and tested study questionnaire.
Hired and trained study coordinators for the project.
• • Obtained Institutional Review Board approval, and annual renewals, from all collaborating institutions.
Created Microsoft Access databases for storing information on study subjects. One database is for recruitment purposes only, and tracks subject's progress through phases of recruitment. Another database stores questionnaire information, and does not have any identifying information.
Built up recruitment database to include contact information for over 3000 potential probands (i.e., index cases with prostate cancer).
Tested and instigated recruitment process for probands and their brothers, whereby initial letters describing the study are followed by phone interviews and/or in person interviews.
Fully recruited 519 men into the study. That is, we have collected and stored consent, blood, and questionnaire information on these men.
Undertaken near-term research looking at relation between a genetic polymorphism and prostate cancer aggressiveness in African-American men. This work indicates that this polymorphism may be involved with aggressiveness, and has been accepted for publication (Appendix).
Became involved with a collaborative effort to map genes for prostate cancer development and aggressiveness.
Reportable Outcomes
To date, our reportable outcomes include the following manuscript and presentations.
• • "Prostate Cancer Genetics." Man-to-Man, Cleveland, Spring 1999.
Conclusions
During the first year of this project we have successfully launched our prostate cancer genetics study. In particular, we have set up and carried out an efficient program for recruiting a large number of brothers into the study. This is important because recruiting a sufficient sample size is critical for the successful completion of the scientific aims of the project. We have attempted to address issues surrounding sample size limitations by extending our recruitment to include older men, non-diseased brothers, and will continue recruiting men well into the second year of the study. While recruitment was underway, we also undertook a project to look for the relation of a genetic polymorphism and prostate cancer aggressiveness among AfricanAmericans. Our findings indicated a positive association between a common single nucleotide poolymorphism in the CYP3A4 gene and tumore grade / stage (Appendix). The value of this knowledge-and the information eventually gleaned from the rest of this project-as a scientific or medical product lies in our ability to use such information to predict which individuals may need more or less serious treatment following diagnosis with prostate cancer. In particular, if men with the observed polymorphism are indeed at an increased risk of prostate cancer aggressiveness, then information about the polymorphism could be used for deciphering the optimal course of clinical treatment.
References
Paris PL, Kupelian PA, Hall JM, Williams TL, Levin H, Klein EA, Casey GC, Witte JS. "Association between a CYP3A4 genetic variant and clinical presentation in African American prostate cancer patients." Cancer Epidemiology, Biomarkers, and Prevention 1999, provisionally accepted. In summary, the CYP3A4 genotype frequency in different ethnic groups broadly followed trends in prostate cancer incidence, presentation and mortality in the U.S. African American prostate cancer patients had a higher frequency of being homozygous for the CYP3A4 variant than healthy African American volunteers who were matched solely based on ethnicity.
DAMD17-98-8589
Abstract
Among the patients, those who were homozygous for the CYP3A4 variant were more likely to present with clinically more advanced prostate cancer.
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Introduction
Prostate cancer is the most common non-skin related cancer affecting men in the United States and the second leading cause of cancer related deaths (1). The incidence of prostate cancer varies substantially across ethnic groups, with African American men exhibiting the highest rates worldwide, and Asian men having the lowest rates (2) . Furthermore, African
American men generally present with more severe forms of prostate cancer, potentially leading to a more aggressive course of the disease (3, 4) . Unfortunately, the etiology of prostate cancer remains unclear, with little known about molecular markers that may help distinguish between an indolent versus an aggressive clinical course. The identification of genetic or molecular risk factors for prostate cancer susceptibility and aggressiveness, including those that distinguish ethnic differences, is an important goal.
Testosterone plays a critical role in stimulating prostate cell division. CYP3A4, a protein belonging to the cytochrome P450 supergene family, is involved in the metabolism and most likely the deactivation of testosterone (5, 6) . A germline genetic variant in the 5' regulatory region of the CYP3A4 gene (A to G transition at position minus 293 from the ATG start site) has recently been reported and was found to be associated with a higher clinical grade and stage in Caucasian men with prostate cancer, especially among those diagnosed at a later age with no family history of the disease (7). Therefore, we examined the genotype frequencies of the CYP3A4 variant in different ethnic groups, and determined that the variant was much more common in African Americans. This motivated us to undertake a study of African Americans that had been diagnosed with prostate cancer, in order to evaluate whether the presence of the 
DNA extraction
For healthy volunteers, DNA was extracted from blood using a kit from Gentra Systems, Inc. (Minnesota). For prostate cancer cases, DNA was extracted from sectioned paraffinembedded tissue blocks (ten 10 micron sections) or pathology slides. Paraffin was removed following treatment with xylene. DNA was then extracted using the QiaAmp Tissue Kit (QIAGEN, California). The final elution was in 50 uL or 100 uL Tris pH 9 buffer for slides or sections, respectively.
CYP3A4 Variant Detection by the TaqMan Assay
The CYP3A4 genotype was determined using the TaqMan assay (10) PSA and TNM stage), and were excluded from the corresponding analyses.
Results
CYP3A4 frequencies among ethnic groups
Genotype frequencies of the CYP3A4 variant across ethnic groups are shown in Table 1 . Taiwanese (12) . This is consistent with the trend that we found in African American, Caucasian, and Asian populations.
Association of CYP3A4 Genotype and Prostate Cancer
Among African Americans with prostate cancer, 83 % (144 of 174) carried at least one copy of the variant allele. Thirty seven percent (64 of 174) of those with a variant were DAMD17-98-8589 heterozygotes, whereas 46 % (80 of 174) were homozygous (Table 1) . Comparing the CYP3A4 genotypes between these men and the African American healthy volunteers gave a two-sided P value = 0.005. Comparing the homozygous (GG) versus the A A and AG combined gave a twosided P-value = 0.002 between these two groups.
Stratification of the CYP3A4 genotypes and clinical characteristics in the 174 African Americans with prostate cancer are shown in data columns 1 through 3 in Table 2 . The fourth column of Table 2 shows ORs comparing GG to AG and AA combined Data restricted to men over the age of 65 are shown in Table 3 . In this group, approximately 10 to 20% more men presented with more severe clinical characteristics if they were homozygous for the variant. Looking at the recessive model, having two copies of the DAMD17-98-8589 CYP3A4 variant was associated with presenting with higher Gleason grade and PSA at diagnosis (ORs = 2.2) (column 4 of Table 3 ). As above, however, the CIs for both of these associations were somewhat wide (lower bounds = 0.9 and 0.8, respectively). We observed a stronger association for grade/stage (OR = 2.4; 95 % CI = 1.1 -5.4 ). The dominant model (i.e. GG and AG versus AA), and a comparison of AG to AA, and GG to AA gave relatively weaker results
(not shown). Additional stratification by family history did not show stronger results.
Discussion
In this study, we show that the frequency of a germline CYP3A4 variant is substantially higher among African American men than among other ethnic groups, and that African Caucasian population (7) . Therefore, the CYP3A4 variant may represent an important prognostic factor for prostate cancer occurrence and aggressiveness among not only Caucasians, but also African Americans. However, these data should be verified in a larger population. In addition, differences in the frequency of the variant between ethnic groups might help to explain some of the inter-ethnic differences in the incidence, presentation, and mortality of this disease.
The CYP3A4 variant reported is an A to G alteration that occurs in the nifedipinespecific element (NFSE) in the 5' regulatory region of the CYP3A4 gene. This element may be required for expression of the CYP3A4 gene (11) . The CYP3A4 protein oxidizes testosterone, which might also deactivate the hormone, although this has yet to be proven (5, 6) . As a result, men carrying the CYP3A4 variant allele may have more testosterone available to be converted to dihydrotestosterone (DHT), which is the main male sex hormone that regulates prostate cell DAMD17-98-8589 division (13) . Consequently, there exists a biological rationale for the CYP3A4 variant playing a role in prostate cancer development and aggressiveness. Metabolism of testosterone may no longer be efficiently processed in men carrying the CYP3A4 variant (especially in those homozygous for the variant), leading to increased prostate cell proliferation due to the increased bioavailability of testosterone. This higher bioavailability may be most important among older men, who due to the aging process have lower basal testosterone levels than younger men (7, 14) . Furthermore, the statistically significant result for African American men with a later age at diagnosis is what one would expect for the CYP3A4 variant because it appears to have a high frequency but low penetrance. That is, many men carry the variant but only some present with more severe clinical characteristics. In contrast, men carrying an uncommon, but highly penetrant genetic mutation (for example HPC1) (15) will be more likely to have an early age of onset and a positive family history of prostate cancer.
The substantial difference in CYP3A4 variant genotype frequencies among the ethnic groups evaluated here was intriguing with regards to the potential involvement of this variant in prostate cancer development. Asians, who have the lowest rates of prostate cancer, were found not to carry the CYP3A4 variant. Some Hispanics and Caucasians, who have prostate cancer incidence rates between Asians and African Americans, carried the variant at a much lower frequency than the African American group. These data are consistent with previously reported findings (12) . Therefore, the frequency of the CYP3A4 variant broadly parallels previously reported (2) incidence rates across ethnic groups in the U.S.
There are a number of limitations to this study. California and Ohio. If the variant is associated with prostate cancer incidence and/or survival, then it will be important to establish the allele frequencies across age groups in future studies.
However, a carefully conducted case-control study will resolve these issues. Second, the associations observed in our evaluation of prostate cancer clinical characteristics were consistent but due to sample size limitations some had broad 95 % confidence intervals. While these associations were modest, the high frequency of the CYP3A4 variant and the increased incidence and mortality of prostate cancer among African Americans suggests an association between disease and the presence of the variant, particularly in homozygous carriers. Third, since most subjects in this study presented with clinically localized disease, we could only compare a moderate range of clinical characteristics, which did not allow for a full analysis of the impact of the CYP3A4 variant on prostate cancer aggressiveness. Finally, the consequences of carrying a particular CYP3A4 genotype may differ depending on the disease or outcome being investigated.
In fact, possession of the wild type genotype has been recently associated with an increased risk for treatment-related (chemotherapy) leukemia (17) .
In summary, African Americans have a higher incidence of prostate cancer and appear to present with more advanced stage disease at time of diagnosis (3, 4) . The data that we present on African American prostate cancer patients, along with other recent work (7), implies that carriers of the CYP3A4 variant are more susceptible to the development of more aggressive forms of this disease. If the association reported here is supported by further research and should prove to be indeed causal, early genetic screening for the CYP3A4 variant may be warranted, and postdiagnostic screening could prove useful in choosing the most appropriate course of treatment.
However, it should be recognized that prostate cancer is a complex disease, and therefore this gene may only play a small part in its etiology.
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